Healthcare
AVITA Medical, Inc.(RCEL)
Live Price
Offline$4.01
+1.78% today
1Y Change
-21.98%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $110.00M
- Revenue Growth
- +11.5%
- EPS Growth
- +27.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AVITA Medical, Inc. (RCEL) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $4.01 and down 22.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +11.5%, EPS growth of +27.2%, a dividend yield of 0.0%. What stands out right now is revenue +11.5%, EPS +27.2%, free cash flow +46.5% with operating margin -59.4% and ROIC 676.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.5. Stock Foundry combines RCEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.5% vs +7.6% peer median
Operating Margin
Below sector median
-59.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.5% and EPS at +27.2%, with operating margin around -59.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +13.8% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +4.6% | +2.8% | -10.3% |
2026 Feb 12, 2026 | -4.3% | +11.8% | +28.8% | +18.3% |
2025 Nov 6, 2025 | -7.0% | +10.9% | +10.0% | +2.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCEL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RCEL Max Drawdown
-51.63%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RCEL and SPY.
Company Overview
AVITA Medical, Inc.
NASDAQ Capital Market
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
- Leadership
- Cary G. Vance
- IPO Date
- May 14, 2012
- Employees
- 260
- Street Address
- 28159 Avenue Stanford
- Mailing
- Valencia, CA, 91355
- Region
- Valencia, CA, US
- Reporting Currency
- USD
- Investor Line
- 661 367 9170
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.5
- Price/Book
- โ
Growth
- Revenue
- +11.5%
- EPS
- +27.2%
- Free Cash Flow
- +46.5%
Profitability
- Gross Margin
- 82.1%
- Operating Margin
- -59.4%
- Net Margin
- -67.8%
- ROE
- 476.6%
- ROIC
- 676.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.